Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Joint WFH-ISTH session: issues in clinical trial design.
Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Peyvandi F, et al. Among authors: farrugia a. Haemophilia. 2014 May;20 Suppl 4:137-44. doi: 10.1111/hae.12415. Haemophilia. 2014. PMID: 24762289 Review.
A study of reported factor VIII use around the world.
Stonebraker JS, Brooker M, Amand RE, Farrugia A, Srivastava A. Stonebraker JS, et al. Among authors: farrugia a. Haemophilia. 2010 Jan;16(1):33-46. doi: 10.1111/j.1365-2516.2009.02131.x. Epub 2009 Oct 21. Haemophilia. 2010. PMID: 19845774
A study of reported factor IX use around the world.
Stonebraker JS, Bolton-Maggs PH, Brooker M, Farrugia A, Srivastava A. Stonebraker JS, et al. Among authors: farrugia a. Haemophilia. 2011 May;17(3):446-55. doi: 10.1111/j.1365-2516.2010.02461.x. Epub 2011 Feb 7. Haemophilia. 2011. PMID: 21299742
Concerns regarding clinical trials in haemophilia-Augmenting Iorio's "Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development" Haemophilia (2017), 1-3 https://doi.org/10.1111/hae.13176.
Farrugia A, Schlenkrich U. Farrugia A, et al. Haemophilia. 2017 Sep;23(5):e475-e476. doi: 10.1111/hae.13306. Epub 2017 Jul 30. Haemophilia. 2017. PMID: 28758308 No abstract available.
Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.
Castaman G, Borchiellini A, Santagostino E, Tagariello G, Serban M, Uscatescu M, Truica C, Farrugia A, Morfini M. Castaman G, et al. Among authors: farrugia a. Haemophilia. 2019 Nov;25(6):e364-e367. doi: 10.1111/hae.13828. Epub 2019 Sep 11. Haemophilia. 2019. PMID: 31509326 No abstract available.
The multiple benefits of sport in haemophilia.
Farrugia A, Gringeri A, von Mackensen S. Farrugia A, et al. Haemophilia. 2018 May;24(3):341-343. doi: 10.1111/hae.13496. Epub 2018 May 6. Haemophilia. 2018. PMID: 29732648 Free article. No abstract available.
The safety of plasma-derived haemophilia factor concentrates - comments on "Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates" Nunes Valença I et al. (2021). Deep viral metagenomics in patients with haemophilia receiving plasma-derived coagulation factor concentrates. Haemophilia. https://doi.org/10.1111/hae.14382.
Farrugia A. Farrugia A. Haemophilia. 2021 Nov;27(6):e760-e761. doi: 10.1111/hae.14400. Epub 2021 Aug 28. Haemophilia. 2021. PMID: 34455649 No abstract available.
285 results